Comprehensive Therapy

, Volume 32, Issue 2, pp 94–101 | Cite as

Pergolide-associated valvular heart disease

Original Articles

Abstract

Pergolide is an ergot derivative dopamine agonist used in the treatment of Parkinson's disease and restless legs syndrome. Ergot derivatives are known to be associated with fibrotic conditions, including a carcinoid-like, fibrotic, valvular heart disease (VHD). Recently, pergolide was identified in association with the development of VHD. This article includes a summary of the literature published on pergolide-associated VHD, a description of the potential mechanisms of drug-induced VHD, and the clinical implications for the management of patients taking pergolide.

Keywords

Bromocriptine Tricuspid Valve Cabergoline Pergolide Ergot Alkaloid 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Connolly HM, Crary JL, McGoon MD, et al. Valvular heart disease associated with fenfluramine-phentermine. N Engl J Med 1997;337: 581–588.PubMedCrossRefGoogle Scholar
  2. 2.
    Bana DS, MacNeal PS, LeCompte PM, et al. Cardiac murmurs and endocardial fibrosis associated with methysergide therapy. Am Heart J 1974;88:640–655.PubMedCrossRefGoogle Scholar
  3. 3.
    Hendrikx M, Van Dorpe J, Flameng W, Daenen W. Aortic and mitral valve disease induced by ergotamine therapy for migraine: a case report and review of the literature. J Heart Valve Dis 1996;5:235–237.PubMedGoogle Scholar
  4. 4.
    Redfield MM, Nicholson WJ, Edwards WD, Tajik AJ. Valve disease associated with ergot alkaloid use: echocardiographic and pathologic correlations. Ann Intern Med 1992;117:50–52.PubMedGoogle Scholar
  5. 5.
    Pritchett AM, Morrison, JF, Edwards WD, et al. Valvular heart disease in patients taking pergolide. Mayo Clin Proc 2002;77:1280–1286.PubMedGoogle Scholar
  6. 6.
    Lang AE, Quinn N, Drincat S, et al. Pergolide in late-stage Parkinson's disease. Ann Neurol 1982;12:243–247.PubMedCrossRefGoogle Scholar
  7. 7.
    Goldstein M, Lieberman A, Lew JY, et al. Interaction of pergolide with central dopaminergic receptors. Proc Natl Acad Sci USA. 1980;77:3725–3728.PubMedCrossRefGoogle Scholar
  8. 8.
    Lieberman A, Goldstein M, Leibowitz M, et al. Treatment of advanced Parkinson's disease. Neurology 1981;31:675–682.PubMedGoogle Scholar
  9. 9.
    Mizuno Y, Kondo T, Narabayashi H. Pergolide in the treatment of Parkinson's disease. Neurology 1995;45(suppl 3):S13-S21.PubMedGoogle Scholar
  10. 10.
    Physician Desk Reference. 60th Edition. Montvale, NJ: Thomson PDR; 2006.Google Scholar
  11. 11.
    Facca A, Sanchez-Ramos J. High dose pergolide monotherapy in the treatment of severe levodopa-induced dyskinesias. Mov Disord 1996;11:327–329PubMedCrossRefGoogle Scholar
  12. 12.
    Schwarz J, Scheidtmann K, Trenkwalder C. Improvement of motor fluctuations in patients with Parkinson's disease following treatment with high doses of pergolide and cessation of levodopa. Eur Neur 1997;37:236–238.CrossRefGoogle Scholar
  13. 13.
    Trenkwalder C, Winkelemann J, Hundemer HP, et al. High-dose treatment of Parkinson's disease with pergolide. Mov Disord. 2000;15:132. Abstract.Google Scholar
  14. 14.
    Wetter TC, Stiasny K, Winkelmann, et al. A Randomized controlled study of pergolide in patients with restless legs syndrome. Neurology 1999;52:944–950.PubMedGoogle Scholar
  15. 15.
    Berezin M, Avidan D, Baron E. Long-term pergolide treatment of hyperprolactinemic patients previously unsuccessful treated with dopaminergic drugs. Isr J Med Sci 1991;27(7):375–379.PubMedGoogle Scholar
  16. 16.
    Pfitzenmeyer P, Foucher P, Dennewald G, et al. Pleuropulmonary changes induced by ergoline drugs. Eur Respir J 1996;9:1013–1019.PubMedCrossRefGoogle Scholar
  17. 17.
    Siberstein SD. Methysergide. Cephalalgia 1998;18:421–435.CrossRefGoogle Scholar
  18. 18.
    Shaunak S, Wilkins A, Piling JB, Dick DJ. Pericardial, retroperitoneal, and pleural fibrosis induced by pergolide. J Neurol Neurosurg Psychiatry 1999;66:79–81.PubMedGoogle Scholar
  19. 19.
    Hoffman W, Trippel O. Retroperitoneal fibrosis aetiological considerations. J Urol 1961;86:222–232.PubMedGoogle Scholar
  20. 20.
    Danoff SK, Grasso Ma, Terry PB, Flynn JA. Pleuropulmonary Disease due to pergolide use for restless legs syndrome. Chest 2001; 120:313–316.PubMedCrossRefGoogle Scholar
  21. 21.
    Morin, LJ, Zuerner, RT. Retroperitoneal fibrosis and carcinoid tumor. JAMA 1971;216:1647.PubMedCrossRefGoogle Scholar
  22. 22.
    Jimenez-Jimenez FJ, Lopez-Alvarez J, Sanchez-Chapado M, et al. Retroperitoneal fibrosis in a patient with Parkinson's disease treated with pergolide. Clin Neuropharmacol 1995;18:277–279.PubMedCrossRefGoogle Scholar
  23. 23.
    Bleumink GS, van der Molen-Eijgenraam M, Strijbos JH, et al. Pergolide-induced Pleuropulmonary fibrosis. Clin Neuropharmacol 2002;25:290–293.PubMedCrossRefGoogle Scholar
  24. 24.
    Serratrice J, Disdier P, Habib G, et al. Fibrotic heart disease subsequent to bromocriptine treatment. Cardiology in Review 2002;10:334–336.PubMedCrossRefGoogle Scholar
  25. 25.
    Flowers CM, Racoosin JA, Lu SL, et al. The US Food and Drug Administration's Registry with pergolide-associated valvular heart disease. Mayo Clin Proc 2003;78:730–731.PubMedGoogle Scholar
  26. 26.
    Robiolio PA, Rigolin VH, Wilson JS, et al. Carcinoid heart disease: correlation of high serotonin levels with valvular abnormalities detected by cardiac catheterization and echocardiography. Circulation 1995;92:790–795.PubMedGoogle Scholar
  27. 27.
    Rothman RB, Baumann MH, Savage JE, et al. Evidence for possible involvement of 5-HT2B receptors in cardiac valvulopathy associated with fenfluramine and other serotonergic medications. Circulation 2000;102:2836–2841.PubMedGoogle Scholar
  28. 28.
    Setola V, Hufeisen SJ, Grande-Allen KJ, et al. 3,4-Methylenedioxymethamphetamine (MDMA, “Ecstasy”) induces fenfluramine-like proliferative actions on human valvular interstitial cells in vitro. Mol Pharmacol 2003;63:1223–1229.PubMedCrossRefGoogle Scholar
  29. 29.
    Van Camp GV, Flamez A, Cosyns B, et al. Treatment of Parkinson's disease with pergolide and relation to restrictive valvular heart disease. The Lancet 2004;363:1179–1183.CrossRefGoogle Scholar
  30. 30.
    Baseman DG, O'Suilleabhain PE, Reimold SC, et al. Pergolide use in Parkinson disease is associated with cardiac valve regurgitation. Neurology 2004;63:301–304.PubMedGoogle Scholar
  31. 31.
    Waller EA, Kaplan J, Heckman MG. Valvular heart disease in patients taking pergolide. Mayo Clin Proc 2005;80(8):1016–1020.PubMedGoogle Scholar
  32. 32.
    Singh JP, Evans JC, Levy D, et al. Prevalence and clinical determinants of mitral, tricuspid, and aortic regurgitation (The Framingham Heart Study). Am J Cardiol 1999;83:897–902.PubMedCrossRefGoogle Scholar
  33. 33.
    Burger AJ, Charlamb MJ, Singh S, et al. Low risk of significant valvulopathy in patients treated with anorectic drugs. Int J Cardiol 2001;71:159–165.CrossRefGoogle Scholar
  34. 34.
    Gardin JM, Schumacher D, Constantine G, et al. Valvular Abnormalities and cardiovascular status following exposure to dexfenfluramine or phentermine/fenfluramine. JAMA 2000;283:1703–1709.PubMedCrossRefGoogle Scholar
  35. 35.
    Jollis JG, Landolfo CK, Kisslo J, et al. Fenfluramine and phentermine and cardiovascular findings: effect of treatment duration on prevalence of valve abnormalities. Circulation 2000;101: 2071–2077.PubMedGoogle Scholar
  36. 36.
    Kancherla, MK, Salti HI, Mulderink, TA, et al. Echocardiographic prevalence of mitral and/or Aortic regurgitation in patients exposed to either fenfluramine-phentermine combination or to dexfenfluramine. Am J Cardiol 1999;84:1335–1338.PubMedCrossRefGoogle Scholar
  37. 37.
    Teramae CY, Connolly HM, Grogan M, and Miller FA. Diet Drug related cardiac valve disease: The Mayo Clinic echocardiographic laboratory experience. Mayo Clin Proc 2000;75:456–461.PubMedGoogle Scholar
  38. 38.
    Van Camp GV, Falmez A, Cosyns B, et al. Heart valvular disease in patients with Parkinson's disease treated with high-dose pergolide. Neurology 2003;61:859–861.PubMedGoogle Scholar
  39. 39.
    Hensrud BB, Connolly HM, Grogan M, et al. Echocardiographic improvement over time after cessation of use of fenfluramine and phentermine. Mayo Clin Proc 1999;74:1191–1197.PubMedCrossRefGoogle Scholar
  40. 40.
    Horvath J, Fross RD, Kleiner-Fisman G, et al. Severe multivalvular heart disease: and new complication of the ergot derivative dopamine agonist. Mov Disorders 2004;19:656–662.CrossRefGoogle Scholar

Copyright information

© ASCMS 2006

Authors and Affiliations

  1. 1.Department of Internal MedicineMayo ClinicJacksonville

Personalised recommendations